Comparative Pharmacology
Head-to-head clinical analysis: AZLIN versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZLIN versus CYCLAPEN W.
AZLIN vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azlin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
1-2 grams intravenously every 4-6 hours; total daily dose up to 12 grams for serious infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1.0–1.5 hours in adults with normal renal function; prolonged to 3–5 hours in moderate renal impairment (CrCl 10–50 mL/min) and up to 10 hours in severe renal impairment (CrCl <10 mL/min).
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Renal excretion of unchanged drug (approximately 60-70% via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <10%.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic